Khoshroo Sara, Sandoughdaran Saleh, Sabetrasekh Parisa, Hajian Parastoo, Bikdeli Pegah, Sabetrasekh Parto, Nasrollahi Fatemeh, Mohammadi Yeganeh Ladan, Naeini Sepideh Jafari, Mirzaei Hamid Reza
Department of Radiation Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Neurological Surgery, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Int J Breast Cancer. 2021 Sep 20;2021:6653265. doi: 10.1155/2021/6653265. eCollection 2021.
This study included patients from two prospective studies conducted in our institute from April 2007 to March 2009. Ninety-one women with axillary lymph node-positive breast cancer who had received four cycles of dose-dense epirubicin and cyclophosphamide were treated with either weekly paclitaxel (80 mg/m) for 12 doses or biweekly docetaxel (75 mg/m) for four cycles.
After a median follow-up of 88 and 109 months, 11 (23.4%) and 10 (22.7%) patients had experienced disease recurrence ( = 0.16), while 10 (21.3%) and 5 (11.4%) patients had died in the paclitaxel and docetaxel arm, respectively ( = 0.56). No significant difference could be seen in 5-year DFS or OS among groups (HR: 0.58; 95% CI: 0.19-1.81, = 0.35; HR: 0.58; 95% CI: 0.19-1.81, = 0.35, respectively).
In conclusion, both evaluated adjuvant chemotherapy regimens have comparable effectiveness regarding DFS and OS.
本研究纳入了2007年4月至2009年3月在我院进行的两项前瞻性研究中的患者。91例腋窝淋巴结阳性乳腺癌女性患者接受了四个周期的密集剂量表柔比星和环磷酰胺治疗，之后分别接受每周一次紫杉醇（80mg/m²）共12剂治疗或每两周一次多西他赛（75mg/m²）共四个周期的治疗。
中位随访88个月和109个月后，紫杉醇组和多西他赛组分别有11例（23.4%）和10例（22.7%）患者出现疾病复发（P = 0.16），分别有10例（21.3%）和5例（11.4%）患者死亡（P = 0.56）。各组间5年无病生存率（DFS）或总生存率（OS）无显著差异（HR：0.58；95%CI：0.19 - 1.81，P = 0.35；HR：0.58；95%CI：0.19 - 1.81，P = 0.35）。
总之，两种评估的辅助化疗方案在DFS和OS方面具有相当的疗效。
